{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:27:45Z","timestamp":1775136465210,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009329","name":"Scientific Research and Technology Development Program of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","award":["2022AC06002"],"award-info":[{"award-number":["2022AC06002"]}],"id":[{"id":"10.13039\/501100009329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","award":["2024GXNSFAA010475"],"award-info":[{"award-number":["2024GXNSFAA010475"]}],"id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00228-024-03725-2","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T14:44:46Z","timestamp":1720190686000},"page":"1461-1469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Time-course and dose-effect of omalizumab in treating chronic idiopathic urticaria\/chronic spontaneous urticaria"],"prefix":"10.1007","volume":"80","author":[{"given":"Aiping","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaihe","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaosi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"issue":"10","key":"3725_CR1","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/j.1398-9995.2009.02178.x","volume":"64","author":"T Zuberbier","year":"2009","unstructured":"Zuberbier T, Asero R, Bindslev-Jensen C et al (2009) EAACI\/GA(2) LEN\/EDF\/WAO guideline: management of urticaria. Allergy 64(10):1427\u20131443","journal-title":"Allergy"},{"issue":"7","key":"3725_CR2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/all.12313","volume":"69","author":"T Zuberbier","year":"2014","unstructured":"Zuberbier T, Aberer W, Asero R et al (2014) The EAACI\/GA(2) LEN\/EDF\/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 69(7):868\u2013887","journal-title":"Allergy"},{"issue":"7","key":"3725_CR3","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/all.13397","volume":"73","author":"T Zuberbier","year":"2018","unstructured":"Zuberbier T, Aberer W, Asero R et al (2018) The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 73(7):1393\u20131414","journal-title":"Allergy"},{"issue":"6","key":"3725_CR4","first-page":"715","volume":"12","author":"KG Bergstrom","year":"2013","unstructured":"Bergstrom KG (2013) Chronic urticaria: omalizumab and review of therapeutic options. J Drugs Dermatol 12(6):715\u2013716","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"3725_CR5","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/all.12870","volume":"71","author":"P Staubach","year":"2016","unstructured":"Staubach P, Metz M, Chapman-Rothe N et al (2016) Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy 71(8):1135\u20131144","journal-title":"Allergy"},{"issue":"1","key":"3725_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/jid.2014.306","volume":"135","author":"SS Saini","year":"2015","unstructured":"Saini SS, Bindslev-Jensen C, Maurer M et al (2015) Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 135(1):67\u201375","journal-title":"J Invest Dermatol"},{"key":"3725_CR7","unstructured":"US FDA (2014) XOLAIR\u00ae (omalizumab) for injection, for subcutaneous use Initial U.S. Approval: 2003. Food and Drug Administration Web. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/103976s5211lbl.pdf. Accessed 18 Mar 2024"},{"issue":"1","key":"3725_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","volume":"132","author":"A Kaplan","year":"2013","unstructured":"Kaplan A, Ledford D, Ashby M et al (2013) Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 132(1):101\u2013109","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3725_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jdermsci.2017.03.009","volume":"87","author":"M Hide","year":"2017","unstructured":"Hide M, Park HS, Igarashi A et al (2017) Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria. J Dermatol Sci 87(1):70\u201378","journal-title":"J Dermatol Sci"},{"issue":"4","key":"3725_CR10","doi-asserted-by":"publisher","first-page":"e15303","DOI":"10.1111\/dth.15303","volume":"35","author":"W Yuan","year":"2022","unstructured":"Yuan W, Hu S, Li M et al (2022) Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria. Dermatol Ther 35(4):e15303","journal-title":"Dermatol Ther"},{"issue":"5","key":"3725_CR11","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.7150\/thno.18304","volume":"7","author":"M Metz","year":"2017","unstructured":"Metz M, Staubach P, Bauer A et al (2017) Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of Fc\u03b5RI-positive cells in the skin. Theranostics 7(5):1266\u20131276","journal-title":"Theranostics"},{"issue":"4","key":"3725_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.anai.2018.06.014","volume":"121","author":"E Nettis","year":"2018","unstructured":"Nettis E, Cegolon L, Di Leo E et al (2018) Omalizumab in chronic spontaneous urticaria: efficacy, safety, predictors of treatment outcome, and time to response. Ann Allergy Asthma Immunol 121(4):474\u2013478","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"3725_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/1203475419888873","volume":"24","author":"A Muntyanu","year":"2020","unstructured":"Muntyanu A, Ouchene L, Ben-Shoshan M, Netchiporouk E (2020) Ligelizumab is superior to omalizumab for chronic spontaneous urticaria. J Cutan Med Surg 24(2):201\u2013202","journal-title":"J Cutan Med Surg"},{"issue":"11","key":"3725_CR14","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/cea.12400","volume":"44","author":"JP Arm","year":"2014","unstructured":"Arm JP, Bottoli I, Skerjanec A et al (2014) Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 44(11):1371\u20131385","journal-title":"Clin Exp Allergy"},{"issue":"14","key":"3725_CR15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","volume":"381","author":"M Maurer","year":"2019","unstructured":"Maurer M, Gim\u00e9nez-Arnau AM, Sussman G et al (2019) Ligelizumab for chronic spontaneous urticaria. N Engl J Med 381(14):1321\u20131332","journal-title":"N Engl J Med"},{"key":"3725_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01684-7","author":"M Maurer","year":"2023","unstructured":"Maurer M, Ensina LF, Gimenez-Arnau AM et al (2023) Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(23)01684-7","journal-title":"Lancet"},{"issue":"5","key":"3725_CR17","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/cpt.1462","volume":"106","author":"VV Upreti","year":"2019","unstructured":"Upreti VV, Venkatakrishnan K (2019) Model-based meta-analysis: optimizing research, development, and utilization of therapeutics using the totality of evidence. Clin Pharmacol Ther 106(5):981\u2013992","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"3725_CR18","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s11095-022-03201-5","volume":"39","author":"P Chan","year":"2022","unstructured":"Chan P, Peskov K, Song X (2022) Applications of model-based meta-analysis in drug development. Pharm Res 39(8):1761\u20131777","journal-title":"Pharm Res"},{"issue":"6","key":"3725_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1398-9995.2008.01726.x","volume":"63","author":"A M\u0142ynek","year":"2008","unstructured":"M\u0142ynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M (2008) How to assess disease activity in patients with chronic urticaria? Allergy 63(6):777\u2013780","journal-title":"Allergy"},{"issue":"1","key":"3725_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/all.13271","volume":"73","author":"T Hawro","year":"2018","unstructured":"Hawro T, Ohanyan T, Schoepke N et al (2018) Comparison and interpretability of the available urticaria activity scores. Allergy 73(1):251\u2013255","journal-title":"Allergy"},{"issue":"12","key":"3725_CR21","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/obr.12606","volume":"18","author":"Z Dong","year":"2017","unstructured":"Dong Z, Xu L, Liu H, Lv Y, Zheng Q, Li L (2017) Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines. Obes Rev 18(12):1377\u20131385","journal-title":"Obes Rev"},{"issue":"2","key":"3725_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10928-010-9152-6","volume":"37","author":"JE Ahn","year":"2010","unstructured":"Ahn JE, French JL (2010) Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation. J Pharmacokinet Pharmacodyn 37(2):179\u2013201","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"3725_CR23","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2(4):e38","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"12","key":"3725_CR24","first-page":"e153","volume":"3","author":"PH Graaf","year":"2014","unstructured":"Graaf PH (2014) Introduction to population pharmacokinetic\/pharmacodynamic analysis with nonlinear mixed effects models. CPT Pharmacometrics Syst Pharmacol 3(12):e153","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"3725_CR25","unstructured":"European Medicines Agency (2014) Xolair (omalizumab) II-48 assessment report. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/xolair-h-c-606-ii-0048-epar-assessment-report-variation_en.pdf. Accessed 18 Mar 2024"},{"issue":"5","key":"3725_CR26","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2500\/aap.2015.36.3873","volume":"36","author":"SD Mathias","year":"2015","unstructured":"Mathias SD, Crosby RD, Ros\u00e9n KE, Zazzali JL (2015) The minimal important difference for measures of urticaria disease activity: updated findings. Allergy Asthma Proc 36(5):394\u2013398","journal-title":"Allergy Asthma Proc"},{"issue":"10","key":"3725_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer M, Ros\u00e9n K, Hsieh HJ et al (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368(10):924\u2013935","journal-title":"N Engl J Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03725-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T06:09:40Z","timestamp":1726121380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03725-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3725"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03725-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable, this study is not a clinical trial.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}}]}}